Natera, Inc.
NTRA · XNASCIK 1604821fmd_064YHVAAEJQGY2PZKJCMVMJE6AServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 213 | 210 | 258 | 302 | 391 | 625 | 820 | 1,083 | 1,697 | 2,306 |
| Cost of revenue | 134 | 136 | 158 | – | – | – | – | – | – | – |
| Gross profit | 78 | 74 | 100 | – | – | – | – | – | – | – |
| Realized investment gains (losses) | 0 | (0) | (0) | 0 | 0 | 0 | (1) | – | – | – |
| Provision for credit losses | – | – | – | – | – | 0 | – | – | – | – |
| Research and development | 42 | 50 | 51 | 51 | 100 | 264 | 316 | 321 | 404 | 624 |
| Selling, general and administrative | 136 | 155 | 155 | 206 | 304 | 511 | 589 | 618 | 841 | 1,177 |
| Operating income | (101) | (135) | (115) | (116) | (216) | (468) | (541) | (446) | (222) | (310) |
| Interest expense | 1 | 4 | 10 | 11 | 15 | 8 | 9 | 13 | 11 | 4 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | (100) | (137) | (128) | (123) | (230) | (471) | (547) | (435) | (190) | (268) |
| Income tax expense | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 1 | (60) |
| Net income from continuing operations | (100) | (138) | (128) | (125) | (230) | (472) | (548) | (435) | (190) | (208) |
| Net income | (100) | (138) | (128) | (125) | (230) | (472) | (548) | (435) | (190) | (208) |
| Net income to common shareholders | (100) | (138) | (128) | (125) | (230) | (472) | (548) | – | – | – |